BRIEF published on 08/15/2026 at 00:55, 1 month 19 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
PRESS RELEASE published on 08/15/2026 at 00:50, 1 month 19 days ago Revive Therapeutics Reports Grant of Options Revive Therapeutics Ltd. authorized the grant of 15,500,000 incentive stock options to key team members. The options aim to drive performance and incentivize excellence in advancing corporate objectives Stock Options Incentive Pandemic Preparedness Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/12/2026 at 14:00, 1 month 22 days ago Revive Therapeutics annonce des résultats d'étude positifs sur la bucillamine pour l'exposition aux agents neurotoxiques Biodefense Bucillamine Revive Therapeutics Recherche Sur Les Agents Neurotoxiques Étude Du DRDC
BRIEF published on 08/12/2026 at 14:00, 1 month 22 days ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
PRESS RELEASE published on 08/12/2026 at 13:55, 1 month 22 days ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
BRIEF published on 07/16/2026 at 00:45, 2 months 18 days ago Revive Therapeutics finalise la première tranche de placements privés Placement Privé Sciences De La Vie Actions Et Bons De Souscription Initiative De Financement Revive Therapeutics
BRIEF published on 07/16/2026 at 00:45, 2 months 18 days ago Revive Therapeutics Completes First Tranche of Private Placement Private Placement Life Sciences Shares And Warrants Funding Initiative Revive Therapeutics
PRESS RELEASE published on 07/16/2026 at 00:40, 2 months 18 days ago Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement Revive Therapeutics Ltd. closes the first tranche of non-brokered private placement, raising $246,920 for infectious diseases and medical countermeasures research and development Private Placement Research And Development Medical Countermeasures Infectious Diseases Revive Therapeutics Ltd.
BRIEF published on 06/26/2026 at 22:20, 3 months 6 days ago Revive Therapeutics propose un placement privé pour lever 1 million de dollars Investissement Actions Placement Privé Sciences De La Vie Revive Therapeutics
BRIEF published on 06/26/2026 at 22:20, 3 months 6 days ago Revive Therapeutics Proposes Private Placement to Raise $1 Million Private Placement Shares Life Sciences Investment Revive Therapeutics
Published on 10/03/2026 at 02:35, 11 hours 57 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 1 hour ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 1 hour ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/02/2026 at 23:55, 14 hours 37 minutes ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 18 hours 8 minutes ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 18 hours 45 minutes ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 19 hours 32 minutes ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 18:00, 20 hours 32 minutes ago EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 17:45, 20 hours 47 minutes ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 20 hours 47 minutes ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 20 hours 57 minutes ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 21 hours 2 minutes ago Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/02/2026 at 17:30, 21 hours 2 minutes ago Aéroports de Paris SA - Calendrier financier 2027
